Clinical trial
A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory…
NCT00482261 · Peter MacCallum Cancer Centre, Australia, Other · Completed
Key facts
| NCT number | NCT00482261 |
|---|---|
| Title | A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression |
| Official title | Phase II Trial of Low Dose Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (Rev-Lite) in Patients at High Risk for Myelosuppression |
| Lead sponsor | Peter MacCallum Cancer Centre, Australia, Other |
| Collaborators | Celgene Corporation Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Lenalidomide, dexamethasone, aspirin |
| Enrollment | 150 |
| Start date | Jun 1, 2007 |
| Primary completion | Aug 1, 2010 |
| Completion | Feb 1, 2014 |
| First posted | Jun 5, 2007 |
| Last update posted | Nov 8, 2024 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: